SCHEMBL15918783

SCHEMBL15918783

CCCCOc1cc(OCCCC)c2c(c1)O[C@H](c1ccc(OCCCC)c(OCCCC)c1)[C@@H](OCCCC)[C@H]2O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.38
▸ SMN1; SMN2 Q16637 4/20 0.34
▸ MAPT P10636 3/20 0.34
▸ HTT P42858 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ CRHBP P24387 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ CRHR2 Q13324 1/20 0.34
▸ PDE4A P27815 1/20 0.34
▸ PDE4B Q07343 1/20 0.34
▸ PDE4C Q08493 1/20 0.34
▸ PDE4D Q08499 1/20 0.34
▸ CYP3A4 P08684 2/20 0.33
▸ MAPK1 P28482 2/20 0.33
▸ KDM4E B2RXH2 2/20 0.32
▸ HPGD P15428 2/20 0.32
▸ AGTR1 P30556 2/20 0.32
▸ LMNA P02545 1/20 0.32
▸ PPARG P37231 2/20 0.32
▸ PPARA Q07869 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15918843 0.95 ALDH1A1 (0.36) ALDH1A1SMN1; SMN2MAPTHTTMEN1
SCHEMBL13508830 0.90 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2MAPTHTTPDE4A
SCHEMBL14626184 0.83 SLC5A2 (0.35) ALDH1A1SMN1; SMN2MAPTHTTMEN1
SCHEMBL14415237 0.83 SLC5A2 (0.35) ALDH1A1SMN1; SMN2MAPTHTTMEN1
SCHEMBL14415238 0.83 SLC5A2 (0.35) ALDH1A1SMN1; SMN2MAPTHTTMEN1
SCHEMBL16160599 0.81 FAAH (0.36) ALDH1A1PPARGPPARAPPARD
SCHEMBL14404262 0.80 MEN1 (0.41) ALDH1A1SMN1; SMN2MEN1KMT2ACYP3A4
SCHEMBL8240944 0.78 CYP3A4 (0.56) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL8247946 0.78 CYP3A4 (0.56) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL14404263 0.78 CYP3A4 (0.56) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9556140-B2 Approach for synthesis of catechins SPHAERA PHARMA PVT. LTD. (IN) 2017-01-31 — — US disclosed
US-20150368223-A1 NOVEL APPROACH FOR SYNTHESIS OF CATECHINS EPIRIUM BIO INC. 2015-12-24 — — US disclosed
WO-2014115174-A2 NOVEL APPROACH FOR SYNTHESIS OF CATECHINS SPHAERA PHARMA PVT. LTD. (IN) 2014-07-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150368223-A1 NOVEL APPROACH FOR SYNTHESIS OF CATECHINS NQO1, COMT, NNMT ALDH1A1 1326/4885SMN1; SMN2 3542/4885MAPT 3520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback